ArticleFrontiers in medicine2022

Development of anti-membrane type 1-matrix metalloproteinase nanobodies as immunoPET probes for triple negative breast cancer imaging.

Francisca Mulero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.